| Returns | 1W : -2.3% , 1M : -3.3%,1Y : 101.9% |
| Peers & Returns | 1W | 1M | 1Y |
| DIVIS LABORATORIES | -2.3% | -3.3% | 101.9% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.6% | -4.3% | 18.1% |
| DRREDDYS LABORATORIES | 5.7% | 15.3% | 89.1% |
| CIPLA | 2% | 2.6% | 69% |
| PIRAMAL ENTERPRISES | -10.1% | -12.6% | -29.3% |
| LUPIN | -2.1% | 4.5% | 37.2% |
| AUROBINDO PHARMA | -3.7% | -10.4% | 29.5% |
| TORRENT PHARMACEUTICALS | -6.3% | -5.2% | 62% |
| CADILA HEALTHCARE | -2.6% | -1.1% | 64.4% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S PEG |
49.95 9.55 13.64 2.44 |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
173% 93% 93% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For Banking industry, Good = Ratio less than 13 Average = Ratio between 13 and 15 Bad = Ratio greater than 15 For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0 0.02 0.01 0.01 |
0 0.02 0.01 0.01 |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As of : July 14,2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Parameter | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
24.25% 36.5% 39.03% 25.64% |
50.01% 74.74% 80.46% 84.12% |
| QtrlyTrend |
8
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Jun2020 | ||
